Home LiteratureArticle Details
PMID: 17698160 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.

Virology ·Vol. 369 ·No. 1 ·2007-12-05 ·Pages 153-67

Lai L, Vödrös D, Kozlowski PA, Montefiori DC, Wilson RL, Akerstrom VL, Chennareddi L, Yu T, Kannanganat S, Ofielu L, Villinger F, Wyatt LS, Moss B, Amara RR, Robinson HL

Abstract

Single intradermal or intramuscular inoculations of GM-CSF DNA with the DNA prime for a simian-human immunodeficiency virus (SHIV)-89.6 vaccine, which consists of DNA priming followed by modified vaccinia Ankara (MVA) boosting, increased protection of both the blood and intestines against the acute phase of an intrarectal SHIV-89.6P challenge. GM-CSF appeared to contribute to protection by enhancing two antibody responses: the avidity maturation of anti-Env IgG in blood (p=or<0.01) and the presence of long lasting anti-viral IgA in rectal secretions (p<0.01). The avidity of anti-Env IgG showed strong correlations with protection both pre and post challenge. Animals with the highest avidity anti-Env Ab had 1000-fold reductions in peak viremia over those with the lowest avidity anti-Env Ab. The enhanced IgA response was associated with the best protection, but did not achieve significance.

MeSH Terms
AIDS Vaccines/genetics,immunology Adjuvants, Immunologic/administration & dosage,genetics Animals Antibodies, Viral/immunology Antibody Affinity/immunology Granulocyte-Macrophage Colony-Stimulating Factor/genetics,immunology Immunization, Secondary Immunoglobulin A/analysis,immunology Immunoglobulin G/blood,immunology Injections, Intradermal Injections, Intramuscular Macaca mulatta Rectum/immunology SAIDS Vaccines/genetics,immunology Simian Acquired Immunodeficiency Syndrome/drug therapy,prevention & control Vaccines, DNA/genetics,immunology Vaccinia virus/genetics,immunology Viral Load Viral Vaccines/genetics,immunology Viremia/immunology
Chemicals
AIDS Vaccines Adjuvants, Immunologic Antibodies, Viral Immunoglobulin A Immunoglobulin G SAIDS Vaccines Vaccines, DNA Viral Vaccines Granulocyte-Macrophage Colony-Stimulating Factor
Authors & Affiliations
15 authors, click to expand affiliations / ORCID
Lai Lilin
Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA; Emory Vaccine Center, 954 Gatewood Road, Atlanta, GA 30322, USA.
Vödrös Dalma
Kozlowski Pamela A
Montefiori David C
Wilson Robert L
Akerstrom Vicki L
Chennareddi Lakshmi
Yu Tianwei
Kannanganat Sunil
Ofielu Lazarus
Villinger Francois
Wyatt Linda S
Moss Bernard
Amara Rama Rao
Robinson Harriet L
References (50)
50 references, click to expand
  1. Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression.
    AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1691-701 PMID: 10606092
  2. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
    AIDS. 1999;13 Suppl A:S137-62 PMID: 10885772
  3. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.
    J Virol. 2000 Aug;74(15):6893-910 PMID: 10888629
  4. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems.
    AIDS Res Hum Retroviruses. 2000 Sep 1;16(13):1247-57 PMID: 10957722
  5. Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody.
    J Acquir Immune Defic Syndr. 2000 Aug 1;24(4):297-309 PMID: 11015145
  6. The antiviral activity of antibodies in vitro and in vivo.
    Adv Immunol. 2001;77:195-262 PMID: 11293117
  7. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
    Science. 2001 Apr 6;292(5514):69-74 PMID: 11393868
  8. Development and homeostasis of T cell memory in rhesus macaque.
    J Immunol. 2002 Jan 1;168(1):29-43 PMID: 11751943
  9. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.
    J Immunol. 2002 Jan 15;168(2):562-8 PMID: 11777947
  10. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
    Infect Immun. 2002 Feb;70(2):584-90 PMID: 11796586
  11. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor.
    Immunol Lett. 2002 Apr 1;81(1):13-24 PMID: 11841841
  12. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.
    J Virol. 2002 Mar;76(6):2683-91 PMID: 11861835
  13. GM-CSF-based cellular vaccines: a review of the clinical experience.
    Cytokine Growth Factor Rev. 2002 Apr;13(2):185-93 PMID: 11900993
  14. Detection of mucosal antibodies in HIV type 1-infected individuals.
    AIDS Res Hum Retroviruses. 2002 Nov 20;18(17):1291-300 PMID: 12487817
  15. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.
    J Immunol. 2004 Mar 15;172(6):3745-57 PMID: 15004179
  16. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.
    J Exp Med. 1992 Dec 1;176(6):1693-702 PMID: 1460426
  17. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 PMID: 8097319
  18. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines.
    Immunity. 1995 Feb;2(2):129-35 PMID: 7895169
  19. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys.
    J Virol. 1996 May;70(5):3198-206 PMID: 8627800
  20. Inability to produce IL-6 is a functional feature of human germinal center B lymphocytes.
    J Immunol. 1996 Jun 1;156(11):4107-13 PMID: 8666776
  21. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.
    J Virol. 1996 Oct;70(10):6922-8 PMID: 8794335
  22. HIV-specific cellular and humoral immune responses in primary HIV infection.
    AIDS Res Hum Retroviruses. 1996 Aug 10;12(12):1129-40 PMID: 8844017
  23. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids.
    J Immunol. 1997 Feb 1;158(3):1231-7 PMID: 9013964
  24. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.
    Springer Semin Immunopathol. 1997;18(3):371-90 PMID: 9089955
  25. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys.
    J Virol. 1997 Jun;71(6):4218-25 PMID: 9151808
  26. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.
    J Virol. 1997 Jul;71(7):5069-79 PMID: 9188572
  27. Cytokines and costimulatory molecules as genetic adjuvants.
    Immunol Cell Biol. 1997 Aug;75(4):397-401 PMID: 9315484
  28. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection.
    J Virol. 1997 Dec;71(12):9508-14 PMID: 9371613
  29. Dendritic cells and the control of immunity.
    Nature. 1998 Mar 19;392(6673):245-52 PMID: 9521319
  30. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.
    J Virol. 1998 May;72(5):3512-9 PMID: 9557629
  31. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus.
    J Immunol. 1998 Jun 15;160(12):6062-71 PMID: 9637523
  32. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine.
    J Immunol. 1998 Sep 1;161(5):2325-32 PMID: 9725227
  33. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene.
    J Virol. 1998 Oct;72(10):8430-6 PMID: 9733898
  34. Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component.
    J Exp Med. 1998 Nov 16;188(10):1895-906 PMID: 9815267
  35. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes.
    Eur J Immunol. 1998 Nov;28(11):3530-40 PMID: 9842896
  36. CSF-1 regulation of Il6 gene expression by murine macrophages: a pivotal role for GM-CSF.
    J Leukoc Biol. 1998 Dec;64(6):810-6 PMID: 9850165
  37. Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis.
    Immunology. 1999 Apr;96(4):511-6 PMID: 10233735
  38. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
    AIDS Res Hum Retroviruses. 2004 Dec;20(12):1335-47 PMID: 15650426
  39. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251.
    J Immunol. 2005 Feb 15;174(4):2185-9 PMID: 15699150
  40. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites.
    Infect Immun. 2005 May;73(5):2863-72 PMID: 15845492
  41. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
    J Virol. 2005 Aug;79(16):10108-25 PMID: 16051804
  42. Mucosal vaccines: the promise and the challenge.
    Nat Rev Immunol. 2006 Feb;6(2):148-58 PMID: 16491139
  43. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine.
    Virology. 2006 Sep 1;352(2):285-94 PMID: 16740288
  44. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells.
    Science. 2006 Nov 17;314(5802):1157-60 PMID: 17110582
  45. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection.
    PLoS Med. 2006 Nov;3(11):e441 PMID: 17121450
  46. Projections of global mortality and burden of disease from 2002 to 2030.
    PLoS Med. 2006 Nov;3(11):e442 PMID: 17132052
  47. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells.
    J Exp Med. 2007 Jan 22;204(1):171-80 PMID: 17190836
  48. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.
    J Immunol. 2007 May 15;178(10):6596-603 PMID: 17475891
  49. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.
    J Virol. 2002 Jun;76(12):6138-46 PMID: 12021347
  50. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen.
    Infect Immun. 2002 Aug;70(8):4329-35 PMID: 12117942
Article Info
Journal
Virology
Abbr.
Virology
ISSN
0042-6822
DOI
10.1016/j.virol.2007.07.017
Published
2007-12-05
Epub
2007-00-14
Pages
153-67
Language
English
Region
United States
NLM ID
0110674
PMCID
PMC2215061
Subset
IM
Grants
NIAID NIH HHS · N01AI30034 · United States
NCRR NIH HHS · P51 RR00165 · United States
NIAID NIH HHS · P01 AI049364-01 · United States
NIAID NIH HHS · R01 AI058896 · United States
NCRR NIH HHS · P51 RR000165-440145 · United States
NIAID NIH HHS · P01 AI049364-03 · United States
NIDA NIH HHS · P30 DA 12121 · United States
NIAID NIH HHS · P01 AI049364 · United States
NIAID NIH HHS · P01 AI049364-02 · United States
NCRR NIH HHS · P51 RR000165-436437 · United States
NCRR NIH HHS · P51 RR000165 · United States
NIAID NIH HHS · P01 AI049364-05 · United States
NCRR NIH HHS · P51 RR000165-465277 · United States
NIAID NIH HHS · P01 AI 49364 · United States
NIAID NIH HHS · R01 AI 58896 · United States
NIAID NIH HHS · P01 AI049364-04 · United States
NCRR NIH HHS · P51 RR000165-450145 · United States
NIAID NIH HHS · R01 AI058896-04 · United States
NIAID NIH HHS · AI 30034 · United States
External Links
PubMed source DOI: 10.1016/j.virol.2007.07.017 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2